Orchard Therapeutics
London, GB · Founded 2018 · Incorporated in United Kingdom · 9 known investors
Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy. The Nasdaq-listed biotech (ticker ORTX) has commercialized therapies including Strimvelis and Libmeldy in Europe.
BiotechDeep TechHealthtechMedical Devices
Founders & leadership
FE
Frank E. ThomasExecutive
SM
Steven M. AltschulerNamed on SEC filing
JC
John CurnutteNamed on SEC filing
DK
Donald KohnScientific Founder
AT
Adrian ThrasherScientific Founder
Board
BG
JA
James A. GeraghtyBoard director
JT
Joanne T. BeckBoard director
MD
Marc DunoyerBoard director
AS
Alicia SecorBoard director
CR
Charles Rowland, Jr.Board director
Investors · 9
Reported raises · per SEC filings
Form D private placements$184M disclosed across 2 rounds · 2021–2023
▶$34MraisedMar 2023 · 7 investors · BiotechnologyRule 506(b)
▶$34MraisedMar 2023 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James A. GeraghtyDirector
- Joanne T. BeckDirector
- Bobby GasparExecutive Officer, Director
- Marc DunoyerDirector
- Steven M. AltschulerDirector
- Frank E. ThomasExecutive Officer
- Alicia SecorDirector
- Charles Rowland, Jr.Director
- John CurnutteDirector
- Amount sold
- $34M
- Sales commissions
- $3.2M
- Placement agents
- GUGGENHEIM SECURITIES, LLC
- First sale
- Mar 2023
- Incorporated
- Other, United Kingdom, 2018
- Federal exemptions
- 06b
▶$150MraisedFeb 2021 · 24 investors · BiotechnologyRule 506(b)
▶$150MraisedFeb 2021 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven AltschulerDirector
- Frank E. ThomasExecutive Officer
- John CurnutteDirector
- Charles Rowland Jr.Director
- Alicia SecorDirector
- Jon EllisDirector
- James A. GeraghtyDirector
- Joanne T. BeckDirector
- Bobby GasparExecutive Officer, Director
- Marc DunoyerDirector
- Offering amount
- $150M
- Amount sold
- $150M
- Sales commissions
- $6M
- Placement agents
- Oppenheimer & Co. Inc., Cantor Fitzgerald & Co., Cowen and Company, LLC
- First sale
- Feb 2021
- Incorporated
- Other, United Kingdom, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapApplied Therapeutics28 shared keywordsApplied Therapeutics is a biopharmaceutical company developing treatments for rare diseases, with a portfolio focused on Classical Galactosemia and CMT-SORD. Its lead investigational drug, govorestat, targets disease pathways such as galactitol and sorbitol reduction.
Bioworld23 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Orchard Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Orchard Therapeutics do?
- Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy. The Nasdaq-listed biotech (ticker ORTX) has commercialized therapies including Strimvelis and Libmeldy in Europe.
- Who are Orchard Therapeutics's investors?
- Orchard Therapeutics's investors include F-Prime Capital, AlbionVC, F-Prime Capital Partners, Foresite Capital, UCL Technology Fund, Agent Capital, Baillie Gifford, ORI Capital and 1 more.
- How much funding has Orchard Therapeutics raised?
- Orchard Therapeutics has disclosed $184M raised across 2 rounds.
- Where is Orchard Therapeutics headquartered?
- Orchard Therapeutics is headquartered in London, GB.